DNLITry to get your head out of the dynamic resistance passing through around 31.9 and stopping at the first static resistance at around 32.60 The rupture of this triangle could lead DNLI towards 38 before 43 according to target otherwise the return to area 26,8Longby Ale_ITPublished 0
$DNLINice and orderly trend change & double bottom right above 200dma. Keep on watch.by RayPublished 0
Falling wedge and possible H&S Denali therapeuticsMy entry and stop on the chart. Im not a financial advisor, please do your own ddLongby ZuccichinUpdated 0
DNLIMID-TERM: Falling wedge, small inverse head and shoulders, bouncing off 200 ma, quadruple classic bullish divergence on MACD. (not financial advice)Longby Champion-VibePublished 3
DNLI a long-term add over 53.50This is not a commentary on the promising fundamentals or potential of Denali Therapeutics but rather a purely technical analysis. DNLI has been consolidating in a falling wedge pattern coming off a nice run up from August of 2020. Price seems to have found a recent bottom at the all-time 50% fib as well a s the 200ema. These are critical levels to hold but so long as it does a bounce out of this wedge pattern seems likely.Longby SpinTradesPublished 2
DNLI, Aroon Indicator entered an Uptrend on December 08, 2020.Over the last three days, Tickeron's A.I.dvisor has detected that DNLI's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron's A.I.dvisor backtested this indicator and found 162 similar cases, 149 of which were successful. Based on this data, the odds of success are 90%. Current price $78.09 is above $43.65 the highest support line found by Tickeron A.I. Throughout the month of 11/05/20 - 12/08/20, the price experienced a +47% Uptrend. During the week of 12/01/20 - 12/08/20, the stock enjoyed a +23% Uptrend growth. Bullish Trend Analysis The Momentum Indicator moved above the 0 level on December 03, 2020. You may want to consider a long position or call options on DNLI as a result. Tickeron A.I. detected that in 37 of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%. DNLI moved above its 50-day Moving Average on August 06, 2020 date and that indicates a change from a downward trend to an upward trend. The 10-day Moving Average for DNLI crossed bullishly above the 50-day moving average on August 10, 2020. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 7 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%. Following a +16.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 152 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 89%. The Aroon Indicator entered an Uptrend today. Tickeron A.I. detected that in 149 of 162 cases where DNLI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.Longby AlTorressPublished 0
DNLI over 62.50After showing some incredible strength in November, DNLI is cooling off forming a bullflag. Over 62.50 should capture the next leg up.Longby SpinTradesPublished 1
DNLI - getting ripe for a rebound soonDNLI appearing to be finding support at the 38% fibonacci retracement level (60.0-60.50). The selling volume has been diminishing and there is also a potential bullish divergence setting up between price anad stochastic. Looking to long at the break above 62.20 with initial stop @ 59.70. Near term target @ 72. Disclaimer: This is just my own analysis and opinion for discussion and is not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance. Thank you. Feel free to comment and join the discussion! :)Longby JuliacPublished 0
DENALI THERAPEUTICS View Hello traders, DENALI THERAPEUTICS is in a historic moment we can witness a high point in its history. It is in a bullish momentum with a larger trace at the bottom than at the top and a large volume of sell at the beginning of the session. On the TIMEFRAME M1 we see the shape of a hammer bear candle and it is about to retest on the stabilization zone. Strong potential to break out the price then the stabilization zone just after to join another. And if the buying force is still present still breakout an area to go and test the symbolic figure of 64.00. Please LIKE & FOLLOW, thank you!Shortby stephanelibatdPublished 0
DNLI - short term swing upDNLI pulled back into support zone 39-40 (horizontal & 50% fib retracement of the recent AB swing up) and started to stage a rebound last Thursday, followed by a retest of the support zone on Fri and again rebounded to close with a bullish dragonfly candlestick. This coupled with bullish divergence between price and RSI increased the odds of a sustainable bounce from here (with a stop loss just below the support zone @ 39). However! (risk disclaimer here) with presidential election and earnings round the corner, it might be prudent keep positions small or scale out at least partially before these events. Disclaimer: This is just my own analysis and opinion for discussion and is not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance. Thank you.Longby JuliacPublished 222
Wall streets darling DNLI halts at key resistanceSince the pandemic March lows, Denali Therapeutics Inc (DNLI) has enjoyed a multi-month rally surpassing it’s January ‘20 highs with ease, amid a bout of increased buying activity following Q2 earnings. As well as individual investors, hedge funds are also optimistic about the future share price of DNLI. Official data shows the number of hedge fund bets increased to seven, meaning the bullish number of hedge funds currently holding positions in the security is at an all-time high. DNLI is currently trading at 41.56 at the time of writing, which is a key level of interest as it tests multi-month fib extension at (3) taken from the highs of January ‘20 at (1) and the lows of March this year at (2). Coupled with that a well-formed rising wedge pattern is in play whereby it’s resistance line junctions exactly at fib extension (3). A break above this dual resistance cluster would be considered all the more bullish, with a view to 45.00 as the next target to watch for. Any pullbacks around these current levels are expected to be shallow and short-lived, providing better buying opportunities for the midterm. Below wedge support throws this bullish outlook into question for the short to midterm. by rapidrunnersPublished 4
The technicals in this biotech stock remind me of Tesla The major pattern above is an ascending broadening wedge just like the pattern in Tesla shown below. Notice Tesla broke out of a major multi year (5 year) consolidation and developed a minor pattern above the breakout. After the minor pattern, Tesla shot to 2k + before announcing their split. Here's the analysis I did on Tesla just after it developed a minor pattern above the ascending broadening wedge: Here is the zoomed in Daily chart of DNLI: This is a confirmed breakout on the smaller time-frame which gives the signal to get long.Longby LanmarUpdated 667
PRECIOUSGold has been accepted as a means of payment for thousands of years, which suggests a certain intrinsic value. The precious metal is currently in particularly high demand. It is true that a well-diversified investment also includes commodities like gold. by ZmdainePublished 6
HUGE VOLATILITYA huge volatility happened today as it reach its peak so far this year. I wonder how far it could possibly go? Could this run well bullish? I'll keep an eye!by itanongsakinPublished 1
Advance DNL151 into Late Stage Clinical Studies in Parkinson’sDenali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients DNL151 selected to advance into two late stage studies Denali and collaboration partner Biogen are finalizing DNL151 clinical development plans and intend to commence patient enrollment in 2021 Denali is currently completing further dose escalation cohorts in an expanded Phase 1 and an additional cohort in the Phase 1b study ---------------------------------------------------------- Biogen Inc. BIIB, announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease. Biogen will make an upfront payment of $560 million, as well as the equity investment from the purchase of 13.3 million newly issued shares, representing about 11% of the shares outstanding, at $34.94 per share, which is 50% above Wednesday's closing price of $23.24. Denali will also be eligible to receive up to $1.125 billion in potential milestone payments depending on the achievement of certain development and commercial milestones. www.marketwatch.com finance.yahoo.com finance.yahoo.com by AlenCikenPublished 0
DNLI: Higher price rejection after gap upHigher price rejection after spike up and gap up. May try to fill the gap. If confirmed: PT1 = 30,01 PT2 = 23,90 (for gap fill)Shortby LeLafPublished 220
FRESH PICKAccording to Zacks Equity Research, it shouldn't be surprising that CDNS is a #2 stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Cadence Design Systems on your short list.by ZmdainePublished 1